SEARCH:   Advanced

Blood, 1 April 2005, Vol. 105, No. 7, pp. 2973-2978. Prepublished online as a Blood First Edition Paper on December 21, 2004; DOI 10.1182/blood-2004-09-3660. This Article Full Text (PDF) Supplemental Data Set All Versions of this Article: 2004-09-3660v1 105/7/2973    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Miklos, D. B Articles by Ritz, J. Search for Related Content PubMed PubMed Citation Articles by Miklos, D. B Articles by Ritz, J. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 28, 2004 Accepted November 30, 2004 Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft versus host disease and disease remission David B Miklos*, Haesook T Kim, Katherine H Miller, Luxuan Guo, Emmanuel Zorn, Stephanie J Lee, Ephraim P Hochberg, Catherine J Wu, Edwin P Alyea, Corey Cutler, Vincent Ho, Robert J Soiffer, Joseph H Antin, and Jerome Ritz Department of Medical Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA Department of Medical Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA, USA * Corresponding author; email: DMiklos{at}Stanford.edu. Minor histocompatibility antigens (mHA) are known targets of donor T cells after allogeneic hematopoietic stem cell transplantation (HSCT). In contrast, B cell responses to mHA have not been extensively characterized and the clinical significance of antibodies to mHA is unknown. We tested 121 HSCT patients and 134 healthy donors for IgG antibodies against 5 mHA encoded by genes on the Y chromosome (DBY, UTY, ZFY, RPS4Y and EIF1AY). Antibodies to at least one H-Y protein developed in 52% of male patients with female donors compared to 8.7% of male patients with male donors (p<0.0001) and in 41.4% of healthy females compared to 7.8% of healthy males (p<0.0001). H-Y antibodies develop 4-12 months after transplantation and persist for long periods. The clinical significance of H-Y antibodies was characterized in 75 male patients with hematologic malignancies who received stem cells from female donors (FM HSCT). The presence of H-Y antibodies correlated with chronic GVHD by univariate (OR=15.5, p<0.0001) and multivariable logistic regression analysis (OR 56.5; p<0.0001). Antibody response to H-Y antigens was also associated with maintenance of disease remission (p<0.0001). B cells may provide a new target for immune intervention in chronic GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: GVHD and relapse: to B or not to B Stephen G. Emerson Blood 2005 105: 2627-2628. [Full Text] [PDF] This article has been cited by other articles: B. Friedrichs, S. Siegel, M. Kloess, A. Barsoum, J. Coggin Jr., J. Rohrer, I. Jakob, M. Tiemann, K. Heidorn, C. Schulte, et al. Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia J. Immunol., May 1, 2008; 180(9): 6374 - 6384. [Abstract] [Full Text] [PDF] K. V. Rosinski, N. Fujii, J. K. Mito, K. K. W. Koo, S. M. Xuereb, O. Sala-Torra, J. S. Gibbs, J. P. Radich, Y. Akatsuka, B. J. Van den Eynde, et al. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells Blood, May 1, 2008; 111(9): 4817 - 4826. [Abstract] [Full Text] [PDF] S. Sarantopoulos, K. E. Stevenson, H. T. Kim, N. S. Bhuiya, C. S. Cutler, R. J. Soiffer, J. H. Antin, and J. Ritz High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease Clin. Cancer Res., October 15, 2007; 13(20): 6107 - 6114. [Abstract] [Full Text] [PDF] M. Y. Mapara Stimulating results with stimulatory antibodies Blood, July 1, 2007; 110(1): 6 - 7. [Full Text] [PDF] J. Chen, F. M. Ellison, M. A. Eckhaus, A. L. Smith, K. Keyvanfar, R. T. Calado, and N. S. Young Minor Antigen H60-Mediated Aplastic Anemia Is Ameliorated by Immunosuppression and the Infusion of Regulatory T Cells J. Immunol., April 1, 2007; 178(7): 4159 - 4168. [Abstract] [Full Text] [PDF] A. Mullally and J. Ritz Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation Blood, February 15, 2007; 109(4): 1355 - 1362. [Abstract] [Full Text] [PDF] Y. Sakoda, D. Hashimoto, S. Asakura, K. Takeuchi, M. Harada, M. Tanimoto, and T. Teshima Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease Blood, February 15, 2007; 109(4): 1756 - 1764. [Abstract] [Full Text] [PDF] C. Cutler, D. Miklos, H. T. Kim, N. Treister, S.-B. Woo, D. Bienfang, L. B. Klickstein, J. Levin, K. Miller, C. Reynolds, et al. Rituximab for steroid-refractory chronic graft-versus-host disease Blood, July 15, 2006; 108(2): 756 - 762. [Abstract] [Full Text] [PDF] J. A. Shizuru Of mice and men Blood, April 1, 2006; 107(7): 2589 - 2590. [Full Text] [PDF] C. J. Wu, L. Krishnamurti, J. L. Kutok, M. Biernacki, S. Rogers, W. Zhang, J. H. Antin, and J. Ritz Evidence for ineffective erythropoiesis in severe sickle cell disease Blood, November 15, 2005; 106(10): 3639 - 3645. [Abstract] [Full Text] [PDF] S. J. Lee New approaches for preventing and treating chronic graft-versus-host disease Blood, June 1, 2005; 105(11): 4200 - 4206. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020